Video

The latest news from lipid-lowering studies with monoclonal antibodies – the PCSK9 inhibitors – is discussed by Dr Peter Lansberg. An update on new devices including a leadless pacemaker and a bioresabsorbable scaffold is reported by Drs Afzal Sohaib and Jubin Joseph, who also talk about advances in the treatment of acute myocardial infarction.

Our latest podcasts are intended to provide an overview of familial hypercholesterolaemia (FH), while reviewing current best treatments as well as some novel options for the future.

Three experts give their personal highlights of the 2015 European Atherosclerosis Society Congress in our podcast.

• Professor Naveed Sattar discusses lifestyle and risk (00:10)
• Professor Børge Nordestgaard discusses the clinical importance of lipoprotein (a) (05:37)
• Professor Derick Raal discusses the launch of the Familial Hypercholesterolaemia Studies Collaboration (10:27)

Highlights of studies presented at the 2014 American Heart Association Scientific Sessions, put into a UK perspective. Professor Tony Wierzbicki talks about the relevance of the IMPROVE-IT study for UK practice, and Professor Robin Choudhury examines the diagnosis of statin intolerance.

Our selection of trials, registry data and guideline updates from the 2014 European Society of Cardiology (ESC) Congress. Professor Keith Fox discusses trials in heart failure, coronary artery disease, and arrhythmia.

Our selection of trials, registry data and guideline updates from the 2014 European Society of Cardiology (ESC) Congress. Dr Christopher Cannon focuses on the ODYSSEY programme, and adherence issues with PCSK9 monoclonal antibody therapies. Professor Kausik Ray puts the key studies into clinical perspective, and explains why the extent – not the means – of LDL cholesterol lowering is key in the prevention of CVD.